Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Compass Pathways
(NASDAQ:CMPS)
Intraday
$7.94
0.08
[1.02%]
After-Hours
$7.94
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$7.94
0.08
[1.02%]
At close: Apr 26
$7.94
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Compass Pathways Stock (NASDAQ:CMPS)
Compass Pathways Stock (NASDAQ: CMPS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 19, 2024
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Caleb Naysmith
-
Apr 19, 2024, 3:23PM
Cantor Fitzgerald Reiterates Overweight on Compass Pathways
Benzinga Newsdesk
-
Apr 19, 2024, 10:40AM
Thursday, April 18, 2024
Cantor Fitzgerald Reiterates Overweight on Compass Pathways
Benzinga Newsdesk
-
Apr 18, 2024, 10:05AM
Wednesday, April 17, 2024
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Lara Goldstein
-
Apr 17, 2024, 8:42AM
Monday, April 15, 2024
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Jelena Martinovic
-
Apr 15, 2024, 8:22PM
Monday, April 01, 2024
COMPASS Pathways shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and announced a $30 price target.
Benzinga Newsdesk
-
Apr 1, 2024, 2:57PM
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
Avi Kapoor
-
Apr 1, 2024, 1:02PM
Morgan Stanley Initiates Coverage On Compass Pathways with Overweight Rating, Announces Price Target of $30
Benzinga Newsdesk
-
Apr 1, 2024, 6:49AM
Saturday, March 30, 2024
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Lara Goldstein
-
Mar 30, 2024, 8:57AM
Friday, March 29, 2024
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Lara Goldstein
-
Mar 29, 2024, 12:43PM
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Lara Goldstein
-
Mar 29, 2024, 9:20AM
Thursday, March 28, 2024
Compass Pathways Board Chair And Co-Founder George Goldsmith And Co-Founder Ekaterina Malievskaia Step Down From Board Of Directors, Effective March 29, 2024
Benzinga Newsdesk
-
Mar 28, 2024, 8:09AM
Wednesday, March 20, 2024
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Lara Goldstein
-
Mar 20, 2024, 2:49PM
Thursday, March 14, 2024
Reported Earlier, 'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
Benzinga Newsdesk
-
Mar 14, 2024, 12:42PM
Wednesday, March 13, 2024
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Lara Goldstein
-
Mar 13, 2024, 11:33AM
Thursday, March 07, 2024
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Lara Goldstein
-
Mar 7, 2024, 1:35PM
Wednesday, March 06, 2024
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
Lara Goldstein
-
Mar 6, 2024, 12:06PM
Monday, March 04, 2024
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Lara Goldstein
-
Mar 4, 2024, 1:48PM
Friday, March 01, 2024
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Benzinga Newsdesk
-
Mar 1, 2024, 2:20PM
Thursday, February 29, 2024
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
Lara Goldstein
-
Feb 29, 2024, 3:16PM
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Feb 29, 2024, 2:00PM
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Lara Goldstein
-
Feb 29, 2024, 11:04AM
Compass Pathways Says Cash Position Of $220.2M At December 31, 2023, And Additional $31.4M Raised To Date In Q14 Fy2024 Is Expected To Provide Cash Runway Into Late 2025
Benzinga Newsdesk
-
Feb 29, 2024, 7:06AM
Compass Pathways Q4 EPS $(0.53) Misses $(0.33) Estimate
Benzinga Newsdesk
-
Feb 29, 2024, 7:04AM
Earnings Scheduled For February 29, 2024
Benzinga Insights
-
Feb 29, 2024, 5:15AM
Wednesday, February 28, 2024
Earnings Preview For Compass Pathways
Benzinga Insights
-
Feb 28, 2024, 12:01PM
Thursday, February 15, 2024
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Lara Goldstein
-
Feb 15, 2024, 8:36AM
Monday, February 12, 2024
'FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says' - Marijuana Moment
Benzinga Newsdesk
-
Feb 12, 2024, 11:38AM
Friday, February 02, 2024
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
Lara Goldstein
-
Feb 2, 2024, 9:49AM
Saturday, January 27, 2024
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Lara Goldstein
-
Jan 27, 2024, 10:00AM
Friday, January 26, 2024
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Lara Goldstein
-
Jan 26, 2024, 12:33PM
Thursday, January 25, 2024
New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy
Lara Goldstein
-
Jan 25, 2024, 9:03AM
Tuesday, January 16, 2024
Compass Pathways Enters Into Research Collaboration Agreement With Hackensack Meridian Health To Develop Clinical Model For Investigational Comp360 Psilocybin Treatment, If FDA Approved
Benzinga Newsdesk
-
Jan 16, 2024, 8:17AM
Monday, January 15, 2024
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Lara Goldstein
-
Jan 15, 2024, 1:38PM
Friday, January 12, 2024
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Lara Goldstein
-
Jan 12, 2024, 4:55PM
Monday, January 08, 2024
Psyched: Psychedelics For Brain Injury, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, $50M For Atai And More
Lara Goldstein
-
Jan 8, 2024, 2:33PM
'New Bipartisan Washington Bill Would Legalize Psilocybin Therapy For Veterans And First Responders' - Marijuana Moment
Benzinga Newsdesk
-
Jan 8, 2024, 1:55PM
Saturday, January 06, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Maureen Meehan
-
Jan 6, 2024, 3:59PM
Friday, January 05, 2024
Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research
Shivani Kumaresan
-
Jan 5, 2024, 10:42AM
Compass Pathways And Greenbrook TMS Enter Into Three-Year Research Collaboration Agreement
Benzinga Newsdesk
-
Jan 5, 2024, 8:18AM
Thursday, January 04, 2024
"DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination" - Marijuana Moment
Benzinga Newsdesk
-
Jan 4, 2024, 11:41AM
Wednesday, January 03, 2024
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect
Lara Goldstein
-
Jan 3, 2024, 5:50PM
Monday, January 01, 2024
Psychedelic Stock Gainers And Losers From January 1, 2024
Benzinga Insights
-
Jan 1, 2024, 4:30PM
Wednesday, December 27, 2023
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
Lara Goldstein
-
Dec 27, 2023, 10:09AM
Tuesday, December 19, 2023
Compass Pathways Announces Investigational COMP360 Psilocybin Treatment Was Well-Tolerated In Phase 2 Study Of Post-Traumatic Stress Disorder
Benzinga Newsdesk
-
Dec 19, 2023, 4:13PM
Do Psychedelic Treatments Always Require Psychotherapy? Well, We Need To Look 'Beyond Reductionism'
Lara Goldstein
-
Dec 19, 2023, 2:44PM
Monday, December 18, 2023
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Lara Goldstein
-
Dec 18, 2023, 12:21PM
Tuesday, December 12, 2023
Compass Pathways shares are trading higher after Deutsche Bank initiated coverage on the stock with a Buy rating and announced a $16 price target.
Benzinga Newsdesk
-
Dec 12, 2023, 12:31PM
Deutsche Bank Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $16
Benzinga Newsdesk
-
Dec 12, 2023, 5:07AM
Monday, December 11, 2023
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
Lara Goldstein
-
Dec 11, 2023, 10:43AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch